Anzeige
Mehr »
Login
Dienstag, 25.02.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
KI-Wunder? Diese Aktie verachtfacht sich nach Deepseek R1-Integration!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Medien-Archiv vom 08.02.2025

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
08.02.How American, Delta, and United Are Prepping for 2025's Super Bowl Surge-
08.02.TENARIS SA - 6-K, Report of foreign issuer-
08.02.PILGRIMS PRIDE CORP - 8-K, Current Report-
08.02.Primo Brands Corp - 8-K, Current Report-
08.02.Kaival Brands Innovations Group, Inc. - 10-K, Annual Report1
08.02.Rexford Industrial Realty, Inc. - 10-K, Annual Report-
08.02.Toleranzia AB: Toleranzia's clinical trial application (CTA) for TOL2 approved in Sweden22Toleranzia AB (the "Company" or "Toleranzia") today announces that the CTA, filed with the European Medicines Agency (EMA) for a clinical trial of the Company's investigational drug TOL2 in patients...
► Artikel lesen
08.02.Regeneron Pharmaceuticals, Inc.: EYLEA HD (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting128TARRYTOWN, N.Y., Feb. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive results from the Phase 3 QUASAR trial investigating...
► Artikel lesen
08.02.Regeneron Pharmaceuticals, Inc.: Three-Year Results for EYLEA HD (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with ...98At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year: 77%...
► Artikel lesen
08.02.4D Molecular Therapeutics, Inc.: 4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program813E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeksIn the recently...
► Artikel lesen
08.02.DASIN RETAIL TRUST: GENERAL ANNOUNCEMENT::UPDATE ON RECEIPT OF REQUISITION FOR AN EGM OF UNITHOLDERS-
08.02.PHILLIP CAPITAL MANAGEMENT (S) LTD: GENERAL ANNOUNCEMENT::NET TANGIBLE ASSETS (NTA) PER UNIT-
08.02.BHARTI AIRTEL LIMITED: GENERAL ANNOUNCEMENT::ALLOTMENT OF EQUITY SHARES UPON CONVERSION OF USD 1,000 MILLION 1.50% CONVERTIBLE BONDS DUE 2025-
08.02.Gold ist nicht zu stoppen82* Ein weiteres Gold-Jahr hat begonnen * Trump kürzt Staatsausgaben * Gold als Underdog * Es ist noch nicht zu spät für den Einstieg Liebe Leser,Mitte dieser Woche ist es schon wieder passiert: Mit einem...
► Artikel lesen
08.02.Ober-Wirtschaftsprüferin im Interview - Bürokratie-Welle trifft Currywurst-Buden5
08.02.Meta plans to lay off five percent of staff from Monday, hire machine learning engineers7
08.02.PlayStation Network suffers major global outage lasting more than a day3
08.02.Erschöpft? Hodl BTC und Berühre Gras1
08.02.Half of the S&P 500 real estate stocks post earnings beat - Earnings Scorecard2
08.02.«De Sänf dezue»: Tele M1 startet neuen regionalen Polit-Talk2
Seite:  Weiter >>